novo nordisk trending in Portugal

Novo Nordisk has become a focal point due to its recent European Union approval for Wegovy, an oral medication aimed at weight management. This pharmaceutical milestone follows the company's significant $5 billion investment activity and expansion into cardiometabolic health with new trials targeting heart failure and obesity. The surge in searches reflects public and investor intent on following the company's progress and the impact of this new drug on weight-loss treatment options.